Oat Protects against Diabetic Nephropathy in Rats via Attenuating Advanced Glycation End Products and Nuclear Factor Kappa B

Al-Malki, Abdulrahman L.

doi:https://doi.org/10.1155/2013/609745

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Materials and Methods Results Discussion References Copyright Related Articles

Special Issue

Natural Products for the Treatment of Obesity, Metabolic Syndrome, and Type 2 Diabetes

View this Special Issue

Research Article | Open Access

Volume 2013 | Article ID 609745 | https://doi.org/10.1155/2013/609745

Oat Protects against Diabetic Nephropathy in Rats via Attenuating Advanced Glycation End Products and Nuclear Factor Kappa B

Abdulrahman L. Al-Malki¹

Academic Editor: Ravirajsinh Jadeja

Received26 Feb 2013

Revised05 Sept 2013

Accepted05 Sept 2013

Published10 Oct 2013

Abstract

Oat, a rich source of soluble fiber, was considered to have a possible preventive effect on the progression of diabetic nephropathy. The present study aimed to assess this preventive activity in a rat model of diabetic nephropathy. Adult Wister rats were injected by streptozotocin (65 mg/kg). Animals were fed with normal diet or with a diet containing 20% oat (W/W) for 21 weeks. At the end of 21 weeks, all the kidney tissues were collected for various examinations. Our results suggested that oat could decrease the Scr and glucose level in blood of diabetic rats significantly (), and increase the creatinine clearance (). In histopathological examination, oat-fed rats showed a significant decrease in glomerulus segmented sclerosis and incidence of tubule vacuolar degeneration. By ELISA, we reported that oat feeding resulted in decreasing the levels of IL-6 and AGE in serum and kidney homogenate. In addition, the levels of oxidative stress markers were markedly improved as a result of oat feeding. Furthermore, using EMSA, we showed that oat attenuated the activation of NF-B. Using RT-PCR, we found that oat could downregulate the TGF-1 and RAGE expression at mRNA levels. This study suggests that oat can suppress diabetic nephropathy in rats effectively and may slow down the renal fibrosis by the disruption of the detrimental AGE-RAGE-NFB axis.

1. Introduction

Diabetic nephropathy (DN) is the most common cause contributing to end-stage renal disease (ESRD) [1]. The chronic hyperglycemia destroys function and structure the kidney, leading to albuminuria which in turn further damages the renal tubular structure [2]. In diabetes, the kidney is a direct target to the enhanced glucose levels. Advanced glycation end products (AGE) are heterogeneous products formed by the nonenzymatic reactions between reducing sugars and free amino groups of proteins, lips, and nucleic acids [3].

AGE have been implicated as one of the major factors in the pathogenesis of numerous pathologies (aging, atherosclerosis, rheumatoid arthritis, and Alzheimer’s disease) notably including diabetic complications [4–6]. AGE can interfere with protein function and promote formation of aggregates. In kidney, AGE can become trapped in glomerular basement membranes and covalently crosslink to collagen resulting in membrane thickening and distortion [7]. In addition to these direct effects, AGE can bind mesangial cell surface receptors stimulating formation of transforming growth factor β1 (TGF-β1) and connective tissue growth factor (CTGF), which in turn mediates mesangial expansion and glomerulosclerosis [8]. Furthermore, AGE interact with their receptor (RAGE) on the cell membrane resulting in activation of the nuclear transcription factor kappa B (NF-κB). NF-κB is found in the cytoplasm of the unactivated cells bound to its inhibitor I-κB. Upon activation, NF-κB migrates to the nucleus where it upregulates the transcription of several inflammatory genes like IL-6, TGFβ, and others [9].

Many AGE inhibitors offer a promising therapeutic approach for diabetes-related complications [10, 11]. AGE-inhibitors include aminoguanidine (AG, Pimagedine) [12], pyridoxamine [13], aspirin [14], OPB9195 [15], and LR compounds [16]. Compounds that break AGE crosslink include phenacylthiazolium bromide (PTB) [17] and ALT-711 (Alagebrium) [18]. Some of the agents targeting AGE have been approved for clinical trials [19].

Cumulative studies demonstrated that dietary fiber can significantly reduce the risk of cardiovascular disease and type 2 diabetes mellitus [20]. This is due in part to the ability of fiber to reduce postprandial glycaemia and improve long-term glycemic control [21, 22]. It was postulated that the rheological properties of soluble dietary fibers are highly related to their effects on control of the glucose concentration [23]. For instance, the ability of oat-derived β-glucan to reduce postprandial glycaemia has been strongly correlated with its viscosity [24], demonstrating an inverse linear relationship between the logarithm of viscosity measures and peak postprandial plasma glucose and insulin responses after consuming various doses of purified oat β-glucan with a 50 g oral glucose load. Despite these findings, the levels of viscosity required to achieve specific glucose-lowering effects are poorly understood. Still, the majority of trials investigating dietary fiber have not accounted for the principles of polysaccharide solubility and viscosity as the main determinants of its physiological outcome. While a small number of studies have shown the effect of oat on diabetes [25, 26], none examined its effect on the development and progression of diabetic nephropathy.

The aim of this study is to evaluate the effect of oat on the hyperglycemia-induced AGE formation and NF-κB activation and if this can attenuate the development of diabetic nephropathy. Because oat is natural dietary supplement and widely used, the results of this study may provide an alternative for enhancing nutrition and diabetic control during diabetic nephropathy.

2. Materials and Methods

2.1. Animals

Adult male Wistar rats (Rattus Rattus) weighing about g were used in the present study. All animals were housed in cages and received normal rat diet and tap water ad libitum in a constant environment (room temperature °C, room humidity %) with a 12 h light, 12 h dark cycle. The animals were kept under observation for two weeks prior to the start of the experiments.

2.2. Induction of Diabetes Model and Study Design

Forty-five Wister rats were used in this experiment. Ten rats were used as normal control group (group 1, ), which received a single ip injection of 0.1 mol/L citrate buffer. A group of 35 rats were intravenously injected with STZ (65 mg/kg body weight) [27] in a 0.1 mol/L citrate buffer (pH 4.5). Only rats with blood glucose higher than 300 mg/dL after 7 days were considered as being diabetic in the fasting state. Glucose measurement was done by using OneTouch Select Analyzer (LifeScan, Inc., UK). Rats with blood glucose lower than 250 mg/dL were excluded from the study (6 rats). All studies were carried out two days after induction of diabetes. Twenty-nine diabetic rats were randomly divided into two groups: diabetic untreated rats ( rats) and diabetic rats that received 20% oat in the diet (W/W) () [28]. Rats were fed with normal rat meal and oat containing diet 20 g for each rat/day for 21 weeks [29]. Body weight blood glucose and HbA1C levels were measured regularly and at the end of the experiment duration. At the end of the experiment (21 weeks after induction of diabetes), animals were sacrificed. Kidneys were dissected and rinsed with ice cold normal saline and then weighed. An index of renal hypertrophy was estimated by comparing the wet weight of the left kidney to the body weight.

2.3. Kidney Homogenate Preparation

One kidney of each group was washed by cold normal saline solution, then it was homogenized in a homogenization buffer (0.05 M Tris-HCl pH 7.9, 25% glycerol, 0.1 mM EDTA, and 0.32 M (NH₄)₂SO₄) containing a protease inhibitor tablet (Roche, Germany). The resulting solution was sonicated in an ice bath for 10 seconds followed by centrifugation at 13000 rpm, 4°C for 5 minutes. The supernatant was aliquoted and stored at −80°C and assayed for protein concentration using BCA kit (Pierce, Rockford, USA) using bovine serum albumin diluted in the lysis buffer as standard. The homogenate was used for the determination of antioxidant biomarkers, concentration of AGE, and level of IL-6 and TGFβ. The other kidney from each group was used for histopathological, isolation of renal DNA, extraction of the nuclear proteins [30].

2.4. Determination of Serum Biomarkers

Blood sample of rats was centrifuged at 8000 rpm for 10 minutes at 4°C, and serum was removed and aliquoted for the respective analytical determinations. The diagnostic kits for determinations of creatinine (Cr) blood urea nitrogen (BUN), sodium, and potassium were purchased from BioSystem (Barcelona, Spain). All analyses were performed according to the instructions of the manufacturer.

2.5. Analysis of Urine Parameters

Before induction of diabetes and the day before the end of the experiment, urine samples were collected by placing the rats in individual metabolic cages for 24 h. The urine albumin concentration was determined using an ELISA kit (Nephrat II, Exocell, Philadelphia, PA, USA) and the concentration of Cr in pooled urine samples was determined by the commercial assay kit. All analyses were performed in accordance with the manuals provided by the manufacturers. The 24 h urinary albumin excretion rate (UAER) was calculated as UAER (μg 24 h − 1) = urinary albumin (μg mL⁻¹) × 24 h urine volume (mL). Cr clearance (Ccr) was calculated using the following equation: Ccr (mL min⁻¹ kg⁻¹) = [urinary Cr (mg dL⁻¹) × urinary volume (mL)/serum Cr (mg dL⁻¹)] × [1000/body weight (g)] × [1/1440 (min)] [31].

2.6. Determination of the Antioxidant Biomarkers

The activities of total SOD, catalase, and GSH-Px as well as the concentrations of MDA and GSH in the kidney homogenate were determined using commercially available kits from BioVision Research Products (Linda Vista Avenue, USA) according to the instructions of the manufacturer [32–36].

2.7. Determination of IL-6 and TGFβ

The levels of IL-6 and TGFβ in the serum and in the kidney homogenate were assayed by using the commercially available ELISA kits from R&D (Mannheim, Germany) according to the instructions of the manufacturer.

2.8. Measurement of Urinary and Renal 8-Hydroxy-2′-Deoxyguanosine

Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels were determined using an ELISA kit from Genox Corporation (Baltimore, MD, USA) according to the method of Vuksan et al. [21] and corrected by using individual urine creatinine concentrations. Extraction of renal DNA was performed using a DNA extraction kit (Promega, Germany) according to the manufacturer’s protocol. The genomic DNA samples from kidney tissue were also used for the determination of 8-OHdG using the competitive ELISA kit [37].

2.9. Determination of AGE in the Kidney Homogenate

The renal AGE level was determined according to previous method [38]. The concentration of AGE was determined by a competitive ELISA assay. The ELISA kit for AGE determination was obtained from Roche Diagnostics (Mannheim, Germany). As a standard, the monomeric epitope N-carboxymethyl-aminocaproate was used.

2.10. Electrophoretic Mobility Shift Assay (EMSA)

Part of the kidney of each group was dissolved in TOTEX buffer (100 mM HEPES-KOH, pH 7.9, 20% glycerol, 0.35 M sodium, chloride, 1% NP 40, 1 mM magnesium chloride, EGTA 0.5 mM, EDTA 0.5 mM, 10 μg/mL leupeptin, 0.2 mM PMSF, and 0.5 mM DTT) for 30 seconds. The lysate was incubated in ice for 0.5 h, vortexed, and centrifuged at 10000 g for five minutes. The supernatant which contained the total liver extract was transferred to a fresh tube and kept at −80°C for EMSA [25]. The extract was used for determining of the binding activity using the NF-κBp65 consensus sequence: 5′-AG TT GA GG GG AC TT TC CC AG GC-3′. The binding specificity of the mixture was ascertained by competition with a 160-fold molar excess of the unlabeled consensus oligo nucleotides as previously described [39, 40]. Incubation was carried out for 30 min at room temperature in a total volume of 15 mL of buffer that contains 12 mM HEPES/NaOH, pH 7.9, 12% glycerol, 60 mM potassium chloride, EDTA 1 mM, dithiothreitol 1 mM, 1.0 mg of poly (dI-dC), and 10,000 cpm of the labeled probe. The DNA/protein complexes were resolved on nondenaturing 5% polyacrylamide gel electrophoresis, performed with 0.5x Tris/borate/EDTA buffer (4.5 mM boric acid, 0.1 mM EDTA, pH 8.0, and 4.5 mM Tris) [41]. The increase in the expression of NFκBp65 gene was determined by a Phosphor Imager using background substract.

2.11. Reverse Transcription Polymerase Chain Reaction

Total RNA of rats in the three groups was isolated from kidney cortex by using TRIzol reagent (Invitrogen, Darmstadt, Germany) according to the manufacturer’s protocol. Gene expressions were determined using real-time quantitative reverse transcription polymerase chain reaction using light cycler and cyber green kit from Roche (Mannheim, Germany). β-actin was used as a reference gene. The transcripts were amplified in a single reaction containing 1 mg cDNA and 0.5 mM each of the sense and antisense primers. PCR was performed at 94°C 1 cycle for five minutes, followed by 33 cycles at 94°C 1 cycle 1 minute, 62°C 1 cycle 1 minute, 72°C 1 cycle 1 minute, and a final extension step at 72°C 1 cycle 20 minutes. An 08% agarose gel electrophoresis in presence of ethidium bromide as a stain was used for separation of the PCR products. A Digital Imaging System (Gel Logic 2200 Pro, Kodak, USA) was used for scanning and analyzing the obtained bands. The band intensities were expressed relative to the intensity of the bands of the control group which was set as 100%. The sequences of the used primers were as follows: TGFβ1 sense 5′-TGGAGCAACATG TGG AAC TC-3′, antisense 5′-GTC AGC AGC CGG TTA CCA-3′; RAGE sense 5′-CAC AGC CCG GAT TG-3′, antisense 5′-GCT GTA GCT GGT GGT CAG AAC A-3′; β-actin sense 5′-GTGCTATGTTGCTCTAGACTTCG-3′, antisense 5′-ATGCCACAGGATTCCATACC-3′.

2.12. Histopathological Examination

Part of the kidneys was fixed in a 10% neutral formaldehyde solution and embedded in paraffin. Sections were cut at 4 mm with a microtome and deparaffined with xylene. They were stained with hematoxylin and eosin (H&E) staining. Stained kidney sections were observed under a light microscope at magnifications of 200x and 400x [42].

2.13. Statistical Analysis

All group values are expressed as the mean ± SD. Data were evaluated using IBM SPSS 20 for windows. An analysis of variance test was performed initially to test for differences in the treatment, and a Tukey post hoc test and Student’s -test were performed to examine whether there were any significant differences between the three groups.

3. Results

3.1. Effects of Oat Feeding on the Blood Glucose and Kidney/Body Weight Ratio

As indicated in Table 1, STZ injection resulted in a nearly 6-fold increase of the fasting blood sugar (FBS) in the rats of group 2. In addition, STZ injection caused a nearly 3-fold increase in the levels of HbA1C. Oat feeding markedly reduced the elevated levels of FBS and HbA1C. The final body weight of the diabetic untreated animals was markedly decreased compared with the normal control rats indicating that these rats suffer from growth retardation as a result of STZ injection. At the end of the experimental period, the kidney/final body weight ratios of the untreated diabetic animals were significantly higher than those of the control rats (). As a result of oat feeding, the diabetic animals in the third group showed a significant reduction of this elevated ratio compared to the diabetic animals of group 2 ().

3.2. Effects of Oat Feeding on the Renal Function

Data in Table 1 showed that the 24-hour Upro, creatinine, Ccr, potassium, and sodium levels were markedly higher in the diabetic untreated group when compared with the normal control group (). Oat feeding obviously reduced these elevated renal biomarkers in the animals of group 3 compared with rats of group 2 ().

3.3. Effects of Oat on Activities of Oxidant/Antioxidant Enzymes

The activity of SOD, catalase, GSH-px, and GST as well as the concentration of GSH was markedly reduced, whereas the concentration of MDA was markedly increased in the kidney homogenate of the diabetic untreated rats (group 2) compared to the control group (group 1) (), suggesting that these rats suffered from oxidative stress (Table 2). As a result of oat feeding, these altered parameters were significantly improved in the animals of group 3 (). The obtained data showed that oat ameliorated oxidative stress in the diabetic rats.

3.4. Effects of Oat on the Urinary and Renal 8-OHdG

The total amounts of urinary 8-OHdG were significantly greater in diabetic rats (group 2) than in the control rats after 21 weeks after the onset of diabetes (). Feeding of oat resulted in the suppression of the increase in urinary excretion of 8-OHdG in the diabetic rats (). In parallel with the urine results, the levels of 8-OHdG in the DNA were markedly increased in the kidney cortex of the diabetic rats. As shown in Figure 1, all the elevated levels of 8-OHdG were normalized by oat feeding ().

3.5. Effect of Oat on the Levels of AGE

As a result of diabetes, the kidneys of diabetic rats are subjected to elevated levels of glucose. The renal levels of AGE and CML were significantly elevated in the STZ-diabetic rats. These elevated levels were effectively lowered by oat feeding for 21 weeks (Table 2).

3.6. Effect of Oat on the Activation of NF-κB

As a result of diabetes, oxidative stress, and high levels of AGE, NF-κB-p65 was markedly activated in the diabatic untreated animals compared with the normal control. Feeding of the diabetic rats with oat in group 3 resulted in a significant reduction of the NF-κB-p65 as indicated in Figures 2(a) and 2(b).

3.7. Effects of Oat Feeding on RAGE and TGF-β in Rats Kidneys

The expression of RAGE and TGF-β1 was significantly higher in the diabetic untreated group compared with the normal control animals. Oat feeding of the animals in group 3 markedly attenuated the expression of both genes compared with the diabetic untreated rats (group 2) as illustrated in Figure 3.

Figure 3

Expression of NF-κB, TGFβ1, and RAGE in the kidney of control, diabetic, and diabetic + oat rats. RT-PCR analysis by using total RNA extracted from the kidney cortex is shown. Data represent the means with SEs of three independent experiments from three different rats. Gene expression is illustrated as a ratio of the integrated density values for the genes in question and the integrated density of the actin values to yield a semiquantitative assessment. A: control, B: diabetic, and C: diabetic + 20% oat.

3.8. Effect of Oat Feeding on Serum and Renal IL-6

As a result of diabetes, inflammation increases and the release of cytokines like IL-6 increases. Data in Table 1 showed that the serum level of IL-6 was markedly increased as a result of diabetes in group 2 compared with the normal control group (). In parallel, the level of IL-6 in the kidney homogenate of rat in group 2 was significantly increased (). Rats of group 3 which fed oat containing diets showed a significantly lower IL-6 levels in both serum and kidney homogenate (Tables 1 and 2) ().

3.9. Histopathological Findings

After feeding with oat for 21 weeks, all the kidneys were collected for histological examination. In diabetes control group, the renal lesions mainly existed in glomerulus and renal tubules. As compared with the diabetes control rats, oat-fed rats showed significantly less severe sclerosis in glomerulus segments. Nevertheless, oat reduced the incidence of tubule vacuolar degeneration and severity level, suggesting some preventive effect on renal tubule lesions. Representative photomicrographs of glomerular changes were shown in Figure 4. The major differences in diabetes controls and oat-fed animals were segmental and diffuse mesangial expansion of the glomeruli. Hypocellular, sclerotic lesions compatible with diabetic glomerulosclerosis were observed in glomeruli of the diabetic animals under a light microscope.

(a)

(b)

(c)

4. Discussion

In the present study, 21 weeks diabetes by STZ produced a diabetic nephropathy which was manifested by increased creatinine, creatinine clearance, serum BUN, and 24 h urinary albumin. Feeding with Oat significantly reversed the alterations of renal function and confers a hypoglycemic effect which contributes at least in part to a reversal of diabetic nephropathy. An increment in the urine albumin excretion in 24 h was significantly aggravated in diabetic nephropathy that is an important sign to indicate progressive damage to glomerular and tubular cells in diabetic kidney. Oat feeding slows down the 24 hour urinary albumin excretion, in association with a significant decline in BUN and creatinine and creatinine clearance in serum, respectively.

Hyperglycemia causes an increased production of free radical which plays a major role in the disruption of the cellular functions of the kidney that correlates to a decline in the endogenous ROS scavengers such as GSH-px, SOD, GST and catalase (Kalia et al., 2004; Cameron et al., 2005; Jandeleit-Dahm et al., 2005). Oxidative stress as indicated by the high levels of 8-OHdG and the overproduction of the superoxide anions is implicated in the pathophysiology of diabetic nephropathy (Vural et al., 2002). Oat feeding confers the benefit to suppress MDA and 8-OHdG production. In addition, the activity of GST, GSH-px catalase, and SOD was elevated which results in the reduction of progression of the renal lesions.

The overproduction of ROS in diabetes results directly in the enhanced formation of AGE [3]. One important receptor for mediating AGE effects is RAGE [24]. RAGE is expressed in the diabetic kidney, both in tubular and in glomerular cells [25]. Binding of AGE such as CML to RAGE augments and propagates oxidative stress in the kidney tissue [25, 26]. RAGE signals via the transcription factor NFκB to activate target genes which have deleterious potential for the diabetic kidney [23, 27, 28]. Feeding with oat reduced RAGE expression, NFκB p65 antigen, and NFκB binding activity. The pivotal role of RAGE in the mediation of ROS/AGE-induced diabetic microangiopathy is supported by experiments using transgenic and knockout mice. RAGE-null mice are protected from diabetes-induced kidney damage (H.-P. Hammes, A. Bierhaus et al., unpublished observations). Thus, our data suggest that part of the beneficial effect of oat includes the disruption of the detrimental AGE-RAGE-NFκB axis.

Activation of NFκB results in its migration into the nucleus. In the nucleus, it upregulates the transcription of its controlled genes like IL-6, TGFβ, and so forth. In the diabetic group, the levels of IL-6 in both serum and kidney homogenate as well as the levels of TGFβ were markedly increased. The results are in line with previous data in parallel with the NFκB results in Figure 2. Feeding with oat reduced AGE and NFκB activation and this resulted in the attenuation of the levels of both cytokine.

Diabetic nephropathy is caused by many factors and cannot be sufficiently controlled with a strict control of hyperglycemia. The early stage diabetic nephropathy is induced by ambient hyperglycemia, but secondary effects are not dependent on persistent hyperglycemia (Vestra and Fioretto, 2003) and it is therefore not enough to merely control serum glucose levels in order to retard the development of diabetic nephropathy. The level of oxidative stress, AGE and NF-κB, together with the elevated levels of cytokine llike IL-6 and TGFβ1, play crucial roles in the functional and pathological damage to the kidney. Feeding with oat slows down the progression of the disease progression by normalizing these abnormalities.

In summary, we provide evidence that ROS scavenging is an effective approach for the prevention of diabetic nephropathy. Oat is a paradigm food supplement with a broad spectrum of beneficial effects, based on its ability to reduce the sequelae of hyperglycaemia-induced ROS overproduction. Since oat also has beneficial effects on other target tissues of diabetic angiopathy and shows beneficial effects on mediators of large vessel damage, this concept appears attractive for the prevention or delay of diabetic angiopathy.

References

M. E. Cooper, “Is diabetic nephropathy disappearing from clinical practice?” Pediatric Diabetes, vol. 7, no. 5, pp. 237–238, 2006.
View at: Publisher Site | Google Scholar
W. Neuhofer and D. Pittrow, “Role of endothelin and endothelin receptor antagonists in renal disease,” European Journal of Clinical Investigation, vol. 36, no. 3, pp. 78–88, 2006.
View at: Publisher Site | Google Scholar
M. Morcos, A. Schlotterer, A. A. Sayed et al., “Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells,” Hormone and Metabolic Research, vol. 40, no. 11, pp. 752–759, 2008.
View at: Google Scholar
N. Ahmed, “Advanced glycation endproducts—role in pathology of diabetic complications,” Diabetes Research and Clinical Practice, vol. 67, no. 1, pp. 3–21, 2005.
View at: Publisher Site | Google Scholar
R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt, “Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation,” Glycobiology, vol. 15, no. 7, pp. 16R–28R, 2005.
View at: Publisher Site | Google Scholar
Y. S. Kanwar, J. Wada, L. Sun et al., “Diabetic nephropathy: mechanisms of renal disease progression,” Experimental Biology and Medicine, vol. 233, no. 1, pp. 4–11, 2008.
View at: Publisher Site | Google Scholar
J. L. Gross, M. J. De Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz, “Diabetic nephropathy: diagnosis, prevention, and treatment,” Diabetes Care, vol. 28, no. 1, pp. 164–176, 2005.
View at: Publisher Site | Google Scholar
F. P. Schena and L. Gesualdo, “Pathogenetic mechanisms of diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 16, no. 3, pp. S30–S33, 2005.
View at: Publisher Site | Google Scholar
M. Morcos, A. A. R. Sayed, A. Bierhaus et al., “Activation of tubular epithelial cells in diabetic nephropathy,” Diabetes, vol. 51, no. 12, pp. 3532–3544, 2002.
View at: Google Scholar
S. Reddy, J. Bichler, K. J. Wells-Knecht, S. R. Thorpe, and J. W. Baynes, “Nε-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins,” Biochemistry, vol. 34, no. 34, pp. 10872–10878, 1995.
View at: Google Scholar
J. Peyroux and M. Sternberg, “Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes,” Pathologie Biologie, vol. 54, no. 7, pp. 405–419, 2006.
View at: Publisher Site | Google Scholar
W. K. Bolton, D. C. Cattran, M. E. Williams et al., “Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy,” American Journal of Nephrology, vol. 24, no. 1, pp. 32–40, 2004.
View at: Publisher Site | Google Scholar
P. A. Voziyan and B. G. Hudson, “Pyridoxamine: the many virtues of a maillard reaction inhibitor,” Annals of the New York Academy of Sciences, vol. 1043, pp. 807–816, 2005.
View at: Publisher Site | Google Scholar
A. Jafarnejad, S. Z. Bathaie, M. Nakhjavani, and M. Z. Hassan, “Investigation of the mechanisms involved in the high-dose and long-term acetyl salicylic acid therapy of type I diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 2, pp. 850–857, 2008.
View at: Publisher Site | Google Scholar
T. Miyata, Y. Ueda, K. Asahi et al., “Mechanism of the inhibitory effect of OPB-9195 [(6)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation,” Journal of the American Society of Nephrology, vol. 11, no. 9, pp. 1719–1725, 2000.
View at: Google Scholar
S. Rahbar, “Novel inhibitors of glycation and AGE formation,” Cell Biochemistry and Biophysics, vol. 48, no. 2-3, pp. 147–157, 2007.
View at: Publisher Site | Google Scholar
S. Yang, J. E. Litchfield, and J. W. Baynes, “AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats,” Archives of Biochemistry and Biophysics, vol. 412, no. 1, pp. 42–46, 2003.
View at: Publisher Site | Google Scholar
M. Peppa, H. Brem, W. Cai et al., “Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711),” American Journal of Nephrology, vol. 26, no. 5, pp. 430–436, 2006.
View at: Publisher Site | Google Scholar
S.-Y. Goh, M. Jasik, and M. E. Cooper, “Agents in development for the treatment of diabetic nephropathy,” Expert Opinion on Emerging Drugs, vol. 13, no. 3, pp. 447–463, 2008.
View at: Publisher Site | Google Scholar
P. Würsch and F. X. Pi-Sunyer, “The role of viscous soluble fiber in the metabolic control of diabetes: a review with special emphasis on cereals rich in β-glucan,” Diabetes Care, vol. 20, no. 11, pp. 1774–1780, 1997.
View at: Google Scholar
V. Vuksan, J. L. Sievenpiper, Z. Xu et al., “Konjac-mannan and American ginseng: emerging alternative therapies for type 2 diabetes mellitus,” Journal of the American College of Nutrition, vol. 20, pp. 370S–380S, 2001.
View at: Google Scholar
D. J. A. Jenkins, T. M. S. Wolever, and A. R. Leeds, “Dietary fibres, fibre analogues, and glucose tolerance: importance of viscosity,” British Medical Journal, vol. 1, no. 6124, pp. 1392–1394, 1978.
View at: Google Scholar
J. Hallfrisch and K. M. Behall, “Mechanisms of the effects of grains on insulin and glucose responses,” Journal of the American College of Nutrition, vol. 19, no. 3, pp. S320–S325, 2000.
View at: Google Scholar
P. J. Wood, J. T. Braaten, F. W. Scott, K. D. Riedel, M. S. Wolynetz, and M. W. Collins, “Effect of dose and modification of viscous properties of oat gum on plasma glucose and insulin following an oral glucose load,” British Journal of Nutrition, vol. 72, no. 5, pp. 731–743, 1994.
View at: Publisher Site | Google Scholar
N. Tapola, H. Karvonen, L. Niskanen, M. Mikola, and E. Sarkkinen, “Glycemic responses of oat bran products in type 2 diabetic patients,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 15, no. 4, pp. 255–261, 2005.
View at: Publisher Site | Google Scholar
S. Panahi, A. Ezatagha, F. Temelli, T. Vasanthan, and V. Vuksan, “β-glucan from two sources of oat concentrates affect postprandial glycemia in relation to the level of viscosity,” Journal of the American College of Nutrition, vol. 26, no. 6, pp. 639–644, 2007.
View at: Google Scholar
A. A. Sayed, “Thymoquinone and proanthocyanidin attenuation of diabetic nephropathy in rats,” Europian Reviews for Medical and Pharmacological Science, vol. 16, no. 6, pp. 808–815, 2012.
View at: Google Scholar
A. L. Almalki, “Oat Attenuation of Hyperglycemia- Induced Retinal Oxidative Stress and NF- $κ$ B activation in Streptozotocin-Induced Diabetic Rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 983923, 8 pages, 2013.
View at: Publisher Site | Google Scholar
A. A. R. Sayed, “Ferulsinaic acid attenuation of diabetic nephropathy,” European Journal of Clinical Investigation, vol. 43, no. 1, pp. 56–63, 2013.
View at: Google Scholar
A. A. R. Sayed, M. Khalifa, and F. F. Abd el-Latif, “Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats—attenuation of diabetic nephropathy in rats,” Journal of Physiology and Biochemistry, vol. 68, no. 2, pp. 263–269, 2012.
View at: Publisher Site | Google Scholar
A. Troudi, I. Ben Amara, A. M. Samet, and N. Zeghal, “Oxidative stress induced by 2,4-phenoxyacetic acid in liver of female rats and their progeny: biochemical and histopathological studies,” Environmental Toxicology, vol. 27, no. 3, pp. 137–145, 2012.
View at: Publisher Site | Google Scholar
D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967.
View at: Google Scholar
M. S. Moron, J. W. Depierre, and B. Mannervik, “Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver,” Biochimica et Biophysica Acta, vol. 582, no. 1, pp. 67–78, 1979.
View at: Google Scholar
A. A. R. Sayed, “Ferulsinaic acid attenuation of advanced glycation end products extends the lifespan of Caenorhabditis elegans,” Journal of Pharmacy and Pharmacology, vol. 63, no. 3, pp. 423–428, 2011.
View at: Publisher Site | Google Scholar
R. A. Mekheimer, A. A. Sayed, and E. A. Ahmed, “Novel 1,2,4-Triazolo [1, 5-a]pyridines and their fused ring systems attenuate oxidative stress and prolong lifespan of Caenorhabiditis elegans,” Journal of Medicinal Chemistry, vol. 55, no. 9, pp. 4169–4177, 2012.
View at: Google Scholar
N. Garrido, A. Pérez-Martos, M. Faro et al., “Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels,” Biochemical Journal, vol. 414, no. 1, pp. 93–102, 2008.
View at: Publisher Site | Google Scholar
T. Matsubasa, T. Uchino, S. Karashima, M. Tanimura, and F. Endo, “Oxidative stress in very low birth weight infants as measured by urinary 8-OHdG,” Free Radical Research, vol. 36, no. 2, pp. 189–193, 2002.
View at: Publisher Site | Google Scholar
A. Schlotterer, G. Kukudov, F. Bozorgmehr et al., “C. elegans as model for the study of high glucose-mediated life span reduction,” Diabetes, vol. 58, no. 11, pp. 2450–2456, 2009.
View at: Publisher Site | Google Scholar
A. A. R. Sayed and M. Morcos, “Thymoquinone decreases AGE-induced NF-κB activation in proximal tubular epithelial cells,” Phytotherapy Research, vol. 21, no. 9, pp. 898–899, 2007.
View at: Publisher Site | Google Scholar
A. A. R. Sayed, “Proanthocyanidin protects against cisplatin-induced nephrotoxicity,” Phytotherapy Research, vol. 23, no. 12, pp. 1738–1741, 2009.
View at: Publisher Site | Google Scholar
A. A. R. Saved, “Thymoquinone protects renal tubular cells against tubular injury,” Cell Biochemistry and Function, vol. 26, no. 3, pp. 374–380, 2008.
View at: Publisher Site | Google Scholar
S. Fukuzawa, Y. Watanabe, D. Inaguma, and N. Hotta, “Evaluation of glomerular lesion and abnormal urinary findings in OLETF rats resulting from a long-term diabetic state,” Journal of Laboratory and Clinical Medicine, vol. 128, no. 6, pp. 568–578, 1996.
View at: Google Scholar

Copyright

Copyright © 2013 Abdulrahman L. Al-Malki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1865

Downloads

1441

Citations